ARTICLE | Emerging Company Profile

Metabolic Solutions: PPAR-less Sensitization

November 23, 2009 8:00 AM UTC

Metabolic Solutions Development Co. has identified an undisclosed mitochondrial target it believes is responsible for many of the beneficial effects of the thiazolidinedione class of diabetes drugs, without the unwanted cardiovascular side effects.

Results from a Phase IIa trial of the company's mitoglitazone, a thiazolidinedione analog selected for preferential binding to the mitochondrial target over PPAR gamma, support its hypothesis. The compound produced glycemic control similar to that of Actos pioglitazone, but produced a better lipid profile and no weight gain or fluid retention...